alexa Targeting DNA Mismatch Repair Deficiency As A Therapeutic Target In Cancer
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Sarah A. Martin
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
The potential of developing a therapy based on targeting the underlying genetic defects, is that it may cause highly selective killing of tumor cells while sparing normal cells, resulting in both increased efficacy and reduced toxicity. The identification of synthetic lethal interactions represents an attractive approach for targeting these deficiencies. Two genes are said to be synthetically lethal if a mutation in either gene alone is compatible with viability but mutation of both causes cell death. This approach has been successfully exploited in the clinic using PARP inhibitors in the treatment of patients with germ line mutations in BRCA1/2. When the genes that mediate the DNA mismatch repair (MMR) pathway, such as MLH1, MSH2 and MSH6 are mutated or epigenetically silenced, the predisposition to cancer is vastly increased. Previously, we have shown that silencing of specific DNA polymerases are synthetically lethal with MMR deficiency via an accumulation of oxidative DNA damage. It has been previously shown that mutations in the MMR gene MSH6 can arise in glioblastomas during temozolomide (TMZ) treatment and can mediate resistance to the drug. Recently, we have identified the thiazole antibiotic, Thiostrepton as synthetically lethal with MSH6 deficiency in our TMZ resistant glioblastoma cells. Our data suggests that this re-sensitization of the TMZ resistant cells is due to a novel regulation of FOXM1, a target of thiostrepton, by MSH6. These synthetic lethal approaches highlight how an understanding of DNA repair processes can be used in the development of novel cancer treatments.
Biography
Sarah Martin completed her Ph.D. in 2003 from the National University of Ireland, Galway and completed postdoctoral studies from Mount Sinai School of Medicine, New York and the Institute of Cancer Research in London. She joined Barts Cancer Institute as a principal investigator in 2010, where she is investigating nuclear and mitochondrial DNA repair as a therapeutic strategy. She has published numerous papers in the area of synthetic lethal targeting and DNA repair deficiency and contributed to many review articles in this area.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords